Terms: = Liver cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Clinical Outcome
24 results:
1. MUC1 triggers lineage plasticity of Her2 positive mammary tumors.
Pang Z; Dong X; Deng H; Wang C; Liao X; Liao C; Liao Y; Tian W; Cheng J; Chen G; Yi H; Huang L
Oncogene; 2022 May; 41(22):3064-3078. PubMed ID: 35461328
[TBL] [Abstract] [Full Text] [Related]
2. Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: a case report.
Van Acker L; Stevens D; Vermaelen K; Surmont V
J Med Case Rep; 2021 Nov; 15(1):562. PubMed ID: 34809713
[TBL] [Abstract] [Full Text] [Related]
3. Immune checkpoints and liver resection after neoadjuvant chemotherapy including bevacizumab in patients with microsatellite-stable colorectal liver metastases.
Stift J; Graf A; Neudert B; Herac M; Woeran K; Tamandl D; Laengle J; Schwarz C; Wrba F; Kaczirek K; Stremitzer S
HPB (Oxford); 2022 Jan; 24(1):40-46. PubMed ID: 34158230
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive functional genomic analyses link APC somatic mutation and mRNA-miRNA networks to the clinical outcome of stage-III colorectal cancer patients.
Chiang SF; Huang HH; Tsai WS; Chin-Ming Tan B; Yang CY; Huang PJ; Yi-Feng Chang I; Lin J; Lu PS; Chin E; Liu YH; Yu JS; Chiang JM; Hung HY; You JF; Liu H
Biomed J; 2022 Apr; 45(2):347-360. PubMed ID: 35550340
[TBL] [Abstract] [Full Text] [Related]
5. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC.
Takeyasu Y; Yoshida T; Shibaki R; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Motoi N; Ohe Y
Clin Lung Cancer; 2021 Mar; 22(2):127-133.e3. PubMed ID: 33183972
[TBL] [Abstract] [Full Text] [Related]
6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract] [Full Text] [Related]
7. Anti-egfr chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial.
Liu Y; Guo Y; Wu Z; Feng K; Tong C; Wang Y; Dai H; Shi F; Yang Q; Han W
Cytotherapy; 2020 Oct; 22(10):573-580. PubMed ID: 32527643
[TBL] [Abstract] [Full Text] [Related]
8. The role of miRNA -31-3p and miR-31-5p in the anti-egfr treatment efficacy of wild-type K-RAS metastatic colorectal cancer. Is it really the next best thing in miRNAs?
Sur D; Cainap C; Burz C; Havasi A; Chis IC; Vlad C; Milosevic V; Balacescu O; Irimie A
J BUON; 2019; 24(5):1739-1746. PubMed ID: 31786833
[TBL] [Abstract] [Full Text] [Related]
9. Efficient Epidermal Growth Factor Receptor Targeting Oligonucleotide as a Potential Molecule for Targeted cancer Therapy.
Wang T; Philippovich S; Mao J; Veedu RN
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31546749
[TBL] [Abstract] [Full Text] [Related]
10. The impact of de novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer.
Chang YP; Chen YM; Lai CH; Lin CY; Fang WF; Huang CH; Li SH; Chen HC; Wang CC; Lin MC
PLoS One; 2017; 12(6):e0178676. PubMed ID: 28591157
[TBL] [Abstract] [Full Text] [Related]
11. egfr and SYNE2 are associated with p21 expression and SYNE2 variants predict post-operative clinical outcomes in HBV-related hepatocellular carcinoma.
Han C; Liao X; Qin W; Yu L; Liu X; Chen G; Liu Z; Lu S; Chen Z; Su H; Zhu G; Lu Z; Liu Z; Qin X; Gui Y; Mo Z; Li L; Peng T
Sci Rep; 2016 Aug; 6():31237. PubMed ID: 27502069
[TBL] [Abstract] [Full Text] [Related]
12. Chemotherapy plus targeted drugs in conversion therapy for potentially resectable colorectal liver metastases: a meta-analysis.
Wang L; Sun Y; Zhao B; Zhang H; Yu Q; Yuan X
Oncotarget; 2016 Aug; 7(34):55732-55740. PubMed ID: 27248177
[TBL] [Abstract] [Full Text] [Related]
13. Impact of epidermal growth factor receptor (egfr) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis.
Castañón E; Rolfo C; Viñal D; López I; Fusco JP; Santisteban M; Martin P; Zubiri L; Echeveste JI; Gil-Bazo I
J Transl Med; 2015 Aug; 13():257. PubMed ID: 26248464
[TBL] [Abstract] [Full Text] [Related]
14. The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy.
Ying HQ; Chen J; He BS; Pan YQ; Wang F; Deng QW; Sun HL; Liu X; Wang SK
Sci Rep; 2015 Jun; 5():11348. PubMed ID: 26076815
[TBL] [Abstract] [Full Text] [Related]
15. HER3 expression in primary colorectal cancer including corresponding metastases in lymph node and liver.
Lédel F; Stenstedt K; Hallström M; Ragnhammar P; Edler D
Acta Oncol; 2015 Apr; 54(4):480-6. PubMed ID: 25601452
[TBL] [Abstract] [Full Text] [Related]
16. Significant renoprotective effect of telbivudine during preemptive antiviral therapy in advanced liver cancer patients receiving cisplatin-based chemotherapy: a case-control study.
Lin CL; Chien RN; Yeh C; Hsu CW; Chang ML; Chen YC; Yeh CT
Scand J Gastroenterol; 2014 Dec; 49(12):1456-64. PubMed ID: 25283499
[TBL] [Abstract] [Full Text] [Related]
17. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract] [Full Text] [Related]
18. clinical impact of hepatitis B and C virus envelope glycoproteins.
Jeulin H; Velay A; Murray J; Schvoerer E
World J Gastroenterol; 2013 Feb; 19(5):654-64. PubMed ID: 23429668
[TBL] [Abstract] [Full Text] [Related]
19. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
Scartozzi M; Giampieri R; Maccaroni E; Mandolesi A; Giustini L; Silva R; Zaniboni A; Biscotti T; Biagetti S; Galizia E; Loupakis F; Falcone A; Bearzi I; Cascinu S
Ann Oncol; 2012 Jul; 23(7):1706-12. PubMed ID: 22112971
[TBL] [Abstract] [Full Text] [Related]
20. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
García-Foncillas J; Díaz-Rubio E
Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
[TBL] [Abstract] [Full Text] [Related]
[Next]